# **Anticancer agent 106**

Cat. No.: HY-149950 Molecular Formula:  $C_{26}H_{25}N_3O_4S$ Molecular Weight: 475.56

Target: **Apoptosis** Pathway: **Apoptosis** 

Storage: Please store the product under the recommended conditions in the Certificate of

Analysis.

**Product** Data Sheet

# **BIOLOGICAL ACTIVITY**

Description

Anticancer agent 106 (compound 10ic) is an anticancer agent that induces apoptosis in B16-F10 melanoma cells. Anticancer agent 106 also potently inhibits metastatic nodules in a mouse model of lung metastatic melanoma. Anticancer agent 106 can be used in the study of cancer, especially lung metastatic melanoma<sup>[1]</sup>.

In Vitro

Anticancer agent 106 (compound 10ic;  $0.28-55~\mu M$ ; 24 h) reduces the viability of B16-F10 melanoma cells in a dosedependent manner, with an IC<sub>50</sub> value of 4.8  $\mu$ M<sup>[1]</sup>.

Anticancer agent 106 (5-20  $\mu$ M; 48 h) induces apoptosis of B16-F10 melanoma cells<sup>[1]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay<sup>[1]</sup>

Cell Line:	B16-F10 melanoma cells
Concentration:	0.28-55 μM
Incubation Time:	24 h
Result:	Inhibited B16-F10 melanoma cells in a dose-dependent manner (IC $_{50}$ = 4.8 $\mu$ M).

### Apoptosis Analysis<sup>[1]</sup>

Cell Line:	B16-F10 melanoma cells
Concentration:	5-20 μM
Incubation Time:	48 h
Result:	Induced cell apoptosis.

In Vivo

Anticancer agent 106 (9-9.5 mg/kg; i.p.; every 3rd d for 22 d) inhibits the metastatic nodules in pulmonary metastatic melanoma mouse model<sup>[1]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	B16-F10 melanoma-bearing C57BL/6 mice (pulmonary metastatic melanoma model) $^{[1]}$ .
---------------	--

Dosage:	9-9.5 mg/kg
Administration:	Intraperitoneal administration; every 3rd d for 22 d.
Result:	Inhibited the lung metastases.

## **REFERENCES**

[1]. Anna Rogova, et al. Synthesis of thieno[3,2-e]pyrrolo[1,2-a]pyrimidine derivatives and their precursors containing 2-aminothiophenes fragments as anticancer agents for therapy of pulmonary metastatic melanoma. Eur J Med Chem. 2023, 254: 115325.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

Page 2 of 2 www.MedChemExpress.com